Company Overview and News

 
The only way to buy property in Shanghai these days is to win the lottery

2018-04-24 cnbc
These days in Shanghai it seems getting a chance to buy property is as close as it gets to winning the lottery.

 
The only way to buy property in Shanghai these days is to win the lottery

2018-04-24 scmp
These days in Shanghai it seems getting a chance to buy property is as close as it gets to winning the lottery.

 
Shanghai developers receive pre-sale permits to begin luxury sales, but there’s a catch

2018-04-11 scmp
A number of luxury Shanghai residential projects have secured permission from authorities to start sales, even as government curbs on the property market in place since last year could mean developers will have to accept lower prices.

 
Shui On shares notch biggest weekly gain after profit beat forecast, even if outlook is modest

2018-03-22 scmp
Shares of Shui On Land, the Hong Kong developer that owns the landmark Shanghai shopping and entertainment district Xintiandi, jumped by their most in a week, after its 2017 profit and sales revenue beat forecasts.

 
Hong Kong’s Shui On buys two Shanghai office towers despite earlier disposals

2017-12-20 scmp
The company says it won a tender to buy two office buildings for US$173m on the same day it announced the disposal of prime Shanghai assets for US$630m

 
Shui On sells prime Shanghai property projects to China Life for 4 billion yuan

2017-12-19 scmp
The sale, which includes three malls, is expected to generate a gain of 1.2 billion yuan for the developer as it pursues an ‘asset-light’ strategy

 
Hong Kong Chief Executive Carrie Lam to deliver welcome address at MIPIM Asia Summit

2017-11-01 marketwired
PARIS, FRANCE--(Marketwired - Nov 1, 2017) - MIPIM Asia Summit 2017 today announces that Mrs Carrie Lam, Chief Executive of the Government of Hong Kong SAR, will attend the event and deliver a welcome address at the opening ceremony.

 
‘It’s my decision’: 97-year-old Lo matriarch says she pushed for lawsuit to dismiss HSBC

2017-06-16 scmp
97-year old widow of the late company founder says there is no truth to suggestions that she has been manipulated to support lawsuit against HSBC

 
Dirty fighting in some of Hong Kong’s wealthiest families may undo value of kinship

2017-06-05 scmp
Family-owned businesses, when they are well-managed and cohesive, can outperform other types of corporate structure, according to a 2015 Credit Suisse report, which studied 920 family-controlled enterprises with at least US$1 billion in market value.

 
Shui On Land sells Chongqing assets to China Vanke for 4.1 billion yuan

2017-05-26 scmp
Shui On Land, the property developer founded by tycoon Vincent Lo Hong-sui, has sold one of its largest mixed commercial projects in mainland China for 4.1 billion yuan (US$596.3 million).

 
Who deserves more? The Lo family is locked in a nasty feud

2017-05-24 scmp
The Lo family of the Great Eagle Group is divided into two opposing camps in the fight for the family wealth, with reconciliation unlikely, according to one son

 
Cover Story – Mapping Out a Business Plan

2017-05-09 scmp
[Sponsored article] Two leading local businessmen who saw, firsthand, the opening up of the Mainland’s own economy, share their take on the OBOR initiative.

 
Cover Story – Mapping Out a Business Plan

2017-05-09 scmp
[Sponsored article] Two leading local businessmen who saw, firsthand, the opening up of the Mainland’s own economy, share their take on the OBOR initiative.

 
Hong Kong developer Shui On sees 38pc rise in annual profit on robust mainland sales

2017-03-22 scmp
Revenue surges 172pc to 18bn yuan. Current landbank sitting at 12.1 million square metres. Rental income rises 6pc to 1.7bn yuan

 
Shui On in talks to sell half its Ruihong project in Shanghai

2017-03-12 scmp
The sale, for an estimated 8 billion yuan, is part of Shui On chairman Vincent Lo’s “asset light” strategy since 2015 to pare the developer’s debt.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...